PFE Jan 2025 35.000 call
- Barrons.com
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.
- Business Wire
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
NEW YORK, June 18, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2024 Performance Report, to be issued that morning.
- Zacks
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
